Allegis Pharmaceuticals, LLC

Allegis Pharmaceuticals, LLC specializes in skin osmotic dressings, specifically non-antimicrobial formulations. These devices are designed for wound care applications, such as managing exudate and maintaining a moist wound environment without incorporating antimicrobial agents. An example of their product is Aladerm Plus, which falls under this category.

Allegis Pharmaceuticals, LLC is headquartered in the United States. Since the company operates within the U.S., its devices are subject to FDA regulations, including classification and listing requirements. The FDA’s Unique Device Identification (UDI) system is used to track these products, ensuring traceability and compliance with U.S. medical device regulations.

Allegis Pharmaceuticals, LLC’s devices are classified under FDA Device Class U (Use Class), which applies to low-risk, non-invasive wound care products like their osmotic dressings. This classification means the devices undergo minimal regulatory scrutiny compared to higher-risk classes (e.g., Class II or III), as they pose a lower risk to patient safety. However, they still must comply with FDA registration, listing, and UDI requirements to ensure proper tracking and market oversight.

Allegis Pharmaceuticals, LLC’s devices are listed in the FDA’s Unique Device Identification (UDI) system, a centralized database that assigns a unique identifier to each medical device to improve tracking, transparency, and post-market surveillance. This system helps healthcare providers, regulators, and manufacturers verify product details, compliance status, and recall information when needed.